In this study, a complementary gene therapy modality using adenovirus-mediated delivery of an IKKβΚA mutant (AdIKKβKA) was deployed to test the extent to which NF-κB inhibition sensitized lung cancer cells to TRAIL (Ad5hTRAIL). This evidence concerns the gene NFKB1 and lung carcinoma.